Group managing director Leonard Ariff Abdul Shatar(pic) said biosimilar products currently contributed 22% of total revenue, and the company planned to gradually increase it to more than 25% through erythropoietin (EPO) treatment registration
SHAH ALAM: CCM Duopharma Biotech Bhd
, which has received shareholders' nod for a name change as part of its corporate rebranding exercise, plans to enter into more niche areas with less competition in order not to be reliant on its generic drug portfolio.
Group managing director Leonard Ariff Abdul Shatar said biosimilar products currently contributed 22% of total revenue, and the company planned to gradually increase it to more than 25% through erythropoietin (EPO) treatment registration.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
